Par Health USA, LLC recalls Buprenorphine HCl
- Published
- 24 Jun 2026
- Units affected
- 46,334 units
- Agency
- FDA
- Country
- United States
The hazard
Crystallization; identified as Buprenorphine free base
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05
- Brand / company
- Par Health USA, LLC
- Codes / lots
- Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027
- Distribution
- Nationwide in the USA.
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 24 Jun 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.